Table 3 Comparison of QoL scores between regimens based on nevirapine or efavirenz over the follow-up period using GEE

PHS

CD4 count <100 cells/μl

NVP

Ref

Ref

EFV

−1.61(−2.82 to −0.40)

−1.61 (−2.74 to −0.49)^a

P = 0.11^d

CD4 count 101–250 cells/μl

NVP

Ref

Ref

EFV

0.17 (−0.70 to 1.05)

0.82 (0.22 to 1.43)^a

P = 0.76^d

CD4 count >250 cells/μl

NVP

Ref

Ref

EFV

0.97 (−0.35 to 2.30)

−1.33 (−5.66 to 3.00)^a

P = 0.90^d

MHS

CD4 count <100 cells/μl

NVP

Ref

Ref

EFV

−0.18 (−1.18 to 0.82)

−0.39 (−1.40 to 0.62)^b

P = 0.91^d

CD4 count 101–250 cells/μl

NVP

Ref

EFV

−0.09 (−0.93 to 0.75)

0.16 (−0.66 to 0.98)^b

P = 0.78^d

CD4 count >250 cells/μl

NVP

Ref

Ref

EFV

−0.84 (−2.09 to 0.42)

−0.75 (−2.01 to 0.51)^b

P = 0.65^d

GPGI

CD4 count <100 cells/μlEFV versus NVP

−0.59 (0.31 to 1.13)

0.51 (0.25 to1.04)^c

P = 0.54^d

CD4 count 101–250 cells/μl

EFV versus NVP

0.85 (0.54 to 1.33)

0.98 (0.60 to 1.56)^c

P = 0.08^d

CD4 count >250 cells/μl

EFV versus NVP

1.30 (0.66 to 2.56)

1.39 (0.66 to 2.90)^c

P = 0.08^d